CHAPTER 4: RNA BASED THERAPEUTICS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast, by Type
4.2. RNA Interference (RNAi)
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. RNA Antisense
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: RNA BASED THERAPEUTICS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast, by end user
5.2. Genetic Disorders
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Auto immune disorders
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
CHAPTER 6: RNA BASED THERAPEUTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast, by end user
6.2. Research Institutes
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Hospitals & Clinics
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
CHAPTER 7: RNA BASED THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast, by region
7.2. North America
7.2.1. Key trends and growth opportunities
7.2.2. Market size and forecast, by type
7.2.3. Market size and forecast, by application
7.2.4. Market size and forecast, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.2. U.S. market size and forecast, by type
7.2.6. Market size and forecast, by application
7.2.6.1. U.S. market size and forecast, by end user
7.2.6.2. Canada
7.2.6.3. Canada market size and forecast, by type
7.2.6.4. Canada market size and forecast, by application
7.2.6.5. Canada market size and forecast, by end user
7.2.6.6. Mexico
7.2.6.7. Mexico market size and forecast, by type
7.2.6.8. Mexico market size and forecast, by application
7.2.6.9. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key trends and growth opportunities
7.3.2. Market size and forecast, by type
7.3.3. Market size and forecast, by application
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Germany.
7.3.5.2. Germany market size and forecast, by type
7.3.5.3. Germany market size and forecast, by application
7.3.5.4. Germany market size and forecast, by end user
7.3.5.5. France
7.3.5.6. France market size and forecast, by type
7.3.5.7. France market size and forecast, by application
7.3.5.8. France market size and forecast, by end user
7.3.5.9. UK
7.3.5.10. UK market size and forecast, by type
7.3.5.11. UK market size and forecast, by application
7.3.5.12. UK market size and forecast, by end user
7.3.5.13. Italy
7.3.5.14. Italy market size and forecast, by type
7.3.5.15. Italy market size and forecast, by application
7.3.5.16. Italy market size and forecast, by end user
7.3.5.17. Spain
7.3.5.18. Spain market size and forecast, by type
7.3.5.19. Spain market size and forecast, by application
7.3.5.20. Spain market size and forecast, by end user
7.3.5.21. Rest of Europe
7.3.5.22. Rest of Europe market size and forecast, by type
7.3.5.23. Rest of Europe market size and forecast, by application
7.3.5.24. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key trends and growth opportunities
7.4.2. Market size and forecast, by type
7.4.3. Market size and forecast, by application
7.4.4. Market size and forecast, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.2. Japan market size and forecast, by type
7.4.5.3. Japan market size and forecast, by application
7.4.5.4. Japan market size and forecast, by end user
7.4.5.5. China
7.4.5.6. China market size and forecast, by type
7.4.5.7. China market size and forecast, by application
7.4.5.8. China market size and forecast, by end user
7.4.5.9. India
7.4.5.10. India market size and forecast, by type
7.4.5.11. India market size and forecast, by application
7.4.5.12. India market size and forecast, by end user
7.4.5.13. Australia
7.4.5.14. Australia market size and forecast, by type
7.4.5.15. Australia market size and forecast, by application
7.4.5.16. Australia market size and forecast, by end user
7.4.5.17. South Korea
7.4.5.18. South Korea market size and forecast, by type
7.4.5.19. South Korea market size and forecast, by application
7.4.5.20. South Korea market size and forecast, by end user
7.4.5.21. Rest of Asia-Pacific
7.4.5.22. Rest of Asia-Pacific market size and forecast, by type
7.4.5.23. Rest of Asia-Pacific market size and forecast, by application
7.4.5.24. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by type
7.5.3. Market size and forecast, by application
7.5.4. Market size and forecast, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.2. Brazil market size and forecast, by type
7.5.5.3. Brazil market size and forecast, by application
7.5.5.4. Brazil market size and forecast, by end user
7.5.5.5. Saudi Arabia
7.5.5.6. Saudi Arabia market size and forecast, by type
7.5.5.7. Saudi Arabia market size and forecast, by application
7.5.5.8. Saudi Arabia market size and forecast, by end user
7.5.5.9. South Africa
7.5.5.10. South Africa market size and forecast, by type
7.5.5.11. South Africa market size and forecast, by application
7.5.5.12. South Africa market size and forecast, by end user
7.5.5.13. Rest of LAMEA
7.5.5.14. Rest of LAMEA market size and forecast, by type
7.5.5.15. Rest of LAMEA market size and forecast, by application
7.5.5.16. Rest of LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. Alnylam Pharmaceuticals Inc
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Arbutus Biopharma Corporation
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Arrowhead Pharmaceuticals
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Benitec Biopharma Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Biogen
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Gradalis, Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segment
8.6.4. Product portfolio
8.7. Genzyme (Sanofi), Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Ionis Pharmaceuticals, Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Sarepta Therapeutics
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Silence Therapeutics plc
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
List of Tables
TABLE 01. RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 02. RNA BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI), BY REGION, 2020-2030($MILLION)
TABLE 03. RNA BASED THERAPEUTICS MARKET FOR RNA ANTISENSE, BY REGION, 2020-2030($MILLION)
TABLE 04. RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 05. RNA BASED THERAPEUTICS MARKET FOR GENETIC DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 06. RNA BASED THERAPEUTICS MARKET FOR AUTO IMMUNE DISORDERS, BY REGION, 2020-2030($MILLION)
TABLE 07. RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030($MILLION)
TABLE 08. RNA BASED THERAPEUTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2030($MILLION)
TABLE 09. RNA BASED THERAPEUTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 10. RNA BASED THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11. NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 12. NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 13. NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14. NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15. U.S. RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 16. U.S. RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 17. U.S. RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 18. CANADA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 19. CANADA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 20. CANADA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 21. MEXICO RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 22. MEXICO RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 23. MEXICO RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 24. EUROPE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 25. EUROPE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 26. EUROPE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 27. EUROPE RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 28. GERMANY RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 29. GERMANY RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 30. GERMANY RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 31. FRANCE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 32. FRANCE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 33. FRANCE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 34. UK RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 35. UK RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 36. UK RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 37. ITALY RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 38. ITALY RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 39. ITALY RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 40. SPAIN RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 41. SPAIN RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 42. SPAIN RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43. REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 44. REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 45. REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 46. ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 47. ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 48. ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 49. ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 50. JAPAN RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 51. JAPAN RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 52. JAPAN RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 53. CHINA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 54. CHINA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 55. CHINA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 56. INDIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 57. INDIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 58. INDIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59. AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 60. AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 61. AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 62. SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 63. SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 64. SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 68. LAMEA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 69. LAMEA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 70. LAMEA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 71. LAMEA RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 72. BRAZIL RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 73. BRAZIL RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 74. BRAZIL RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 75. SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 76. SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 77. SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 78. SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 79. SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 80. SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 81. REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 82. REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 83. REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 84. ALNYLAM: COMPANY SNAPSHOT
TABLE 85. ALNYLAM: OPERATING SEGMENTS
TABLE 86. ALNYLAM: PRODUCT PORTFOLIO
TABLE 87. ALNYLAM.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 88. ARBUTUS: COMPANY SNAPSHOT
TABLE 89. ARBUTUS SEGMENTS
TABLE 90. ARBUTUS: PRODUCT PORTFOLIO
TABLE 91. ARROWHEAD: COMPANY SNAPSHOT
TABLE 92. ARROWHEAD: OPERATING SEGMENT
TABLE 93. ARROWHEAD: PRODUCT PORTFOLIO
TABLE 94. BENITEC: COMPANY SNAPSHOT
TABLE 95. BENITEC: OPERATING SEGMENTS
TABLE 96. BENITEC: PRODUCT PORTFOLIO
TABLE 97. BIOGEN: COMPANY SNAPSHOT
TABLE 98. BIOGEN: OPERATING SEGMENTS
TABLE 99. BIOGEN: PRODUCT PORTFOLIO
TABLE 100. GRADALIS: COMPANY SNAPSHOT
TABLE 101. GRADALIS: OPERATING SEGMENT
TABLE 102. GRADALIS: PRODUCT PORTFOLIO
TABLE 103. GENZYME: COMPANY SNAPSHOT
TABLE 104. GENZYME: OPERATING SEGMENTS
TABLE 105. SANOFI: PRODUCT PORTFOLIO
TABLE 106. SANOFI.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107. IONIS: COMPANY SNAPSHOT
TABLE 108. IONIS: OPERATING SEGMENTS
TABLE 109. IONIS: PRODUCT PORTFOLIO
TABLE 110. SAREPTA: COMPANY SNAPSHOT
TABLE 111. SAREPTA: OPERATING SEGMENT
TABLE 112. SAREPTA: PRODUCT PORTFOLIO
TABLE 113. SAREPTA.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. SILENCE: COMPANY SNAPSHOT
TABLE 115. SILENCE OPERATING SEGMENTS
TABLE 116. SILENCE: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. RNA BASED THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES: BY DEVELOPMENT, 2018-2021 (%)
FIGURE 04. TOP WINNING STRATEGIES: BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05. TOP INVESTMENT POCKETS WINNING STRATEGIES: BY COMPANY, 2018-2021 (%)
FIGURE 06. TOP PLAYER POSITIONING, 2020
FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. HIGH BARGAINING POWER OF BUYERS
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE THREAT OF SUBSTITUTES
FIGURE 11. MODERATR INTENSITY OF COMPETITIVE RIVALRY
FIGURE 12. IMPACT ANALYSES, RNA BASED THERAPEUTICS MARKET
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RNA ANTISENSE BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR GENETIC DISORDERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR AUTO IMMUNE DISORDERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RESEARCH INSTITUTES BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2020 & 2030 (%)
FIGURE 19. ALNYLAM: NET SALES, 2018-2020 ($MILLION)
FIGURE 20. ALNYLAM: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21. ARBUTUS: NET SALES, 2018-2020 ($MILLION)
FIGURE 22. ARROWHEAD: NET SALES, 2018-2020 ($MILLION)
FIGURE 23. BENITEC: NET SALES, 2018-2020 ($MILLION)
FIGURE 24. BIOGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 25. BIOGEN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 26. GENZYME: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. GENZYME: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28. GENZYME: REVENUE SHARE BY REGION, 2020(%)
FIGURE 29. IONIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 30. IONIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31. SAREPTA: NET SALES, 2018-2020 ($MILLION)